Mark A Socinski

Mark A Socinski

UNVERIFIED PROFILE

Are you Mark A Socinski?   Register this Author

Register author
Mark A Socinski

Mark A Socinski

Publications by authors named "Mark A Socinski"

Are you Mark A Socinski?   Register this Author

100Publications

3073Reads

8Profile Views

Atezolizumab Treatment of Nonsquamous NSCLC.

N Engl J Med 2018 09;379(12):1188

Florida Hospital Cancer Institute, Orlando, FL

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMc1809195
Publisher Site
http://dx.doi.org/10.1056/NEJMc1809195DOI Listing
September 2018

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.

N Engl J Med 2018 Jun 4;378(24):2288-2301. Epub 2018 Jun 4.

From the Florida Hospital Cancer Institute, Orlando (M.A.S.); Rocky Mountain Cancer Centers, Denver (R.M.J.); US Oncology, Houston (R.M.J.); Azienda Unità Sanitaria Locale della Romagna, Ravenna, Italy (F.C.); Instituto Nacional del Torax, Santiago, Chile (F.O.); Moscow City Oncology Hospital, Moscow (D.S.); National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan (N.N.); Complejo Hospitalario Universitario Insular Materno-Infantil de Gran Canaria, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain (D.R.-A.); Centre Hospitalier Universitaire de Grenoble Alpes, Grenoble (D.M.-S.), and Aix Marseille University, Assistance Publique-Hôpitaux de Marseille, Marseille (F.B.) - both in France; New England Cancer Specialists, Scarborough, ME (C.A.T.); Allegheny Health Network Cancer Institute, Pittsburgh (G.F.); Genentech, South San Francisco, CA (C.K., A.L., S.C., Y.D., Y.S., M.K., A.L.-C., A.S.); and Lung Clinic Grosshansdorf, Airway Research Center North, German Center of Lung Research, Grosshansdorf, Germany (M.R.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1716948
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1716948DOI Listing
June 2018

PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer.

Mol Diagn Ther 2018 02;22(1):1-10

University of Pittsburgh Cancer Institute, 5150 Centre Ave, Pittsburgh, PA, 15232, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40291-017-0308-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5773410PMC
February 2018

EGFR Gene Copy Number by FISH May Predict Outcome of Necitumumab in Squamous Lung Carcinomas: Analysis from the SQUIRE Study.

J Thorac Oncol 2018 02 20;13(2):228-236. Epub 2017 Nov 20.

Division of Medical Oncology, Department of Medicine, Anschutz Medical Campus, University of Colorado, Aurora, Colorado. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2017.11.109DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6233716PMC
February 2018

Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial.

J Clin Oncol 2017 Nov 11;35(31):3591-3600. Epub 2017 Sep 11.

Federica Grosso, Azienda Ospedaliera SS Antonio e Biagio General Hospital, Alessandria; Silvia Novello and Giorgio Scagliotti, L'università di Torino, Azienda Sanitaria Ospedale San Luigi Gonzaga, Turin, Italy; Anna K. Nowak, University of Western Australia, Crawley, and Sir Charles Gairdner Hospital, Nedlands, Western Australia; Thomas John, Olivia Newton-John Cancer Research Institute, Austin Hospital, Heidelberg, Victoria, Australia; Sanjay Popat, The Royal Marsden Hospital National Health Service (NHS) Foundation Trust, London; Nicola Steele, The Beatson West of Scotland Cancer Centre, Glasgow; Paul Taylor, University Hospitals of South Manchester NHS Trust, Wythenshawe, Manchester, United Kingdom; Laurent Greillier, Assitance Publique Hôpitaux de Marseille, Aix Marseille University, Marseille; David Planchard, Institut Gustave Roussy, Villejuif; Nassim Morsli, Boehringer Ingelheim France S.A.S., Paris, France; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Martin Reck, Lung Clinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf; Ute von Wangenheim, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany; Jens Benn Sørensen, Rigshospitalet - Finsencentret, Copenhagen, Denmark; Mark A. Socinski, Florida Hospital Cancer Institute, Orlando, FL; Arsène Bienvenu Loembé, Boehringer Ingelheim B.V., Alkmaar, the Netherlands; and José Barrueco, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.72.9012DOI Listing
November 2017

How I treat stage IV non-small cell lung cancer in the absence of any actionable oncogenic driver.

Authors:
Mark A Socinski

Clin Adv Hematol Oncol 2017 Oct;15(10):759-765

Florida Hospital Cancer Institute, Orlando, Florida.

View Article

Download full-text PDF

Source
October 2017

Phase 2 study of intermittent pulse dacomitinib in patients with advanced non-small cell lung cancers.

Lung Cancer 2017 10 23;112:195-199. Epub 2017 Aug 23.

Lombardi Comprehensive Cancer Center, Georgetown University, 3970 Reservoir Road Washington DC 20007, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2017.08.017DOI Listing
October 2017

Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies.

J Clin Oncol 2017 Sep 11;35(25):2885-2892. Epub 2017 May 11.

Thomas E. Stinchcombe, Neal E. Ready, and Harvey J. Cohen, Duke University Medical Center; Xiaofei Wang, Alliance Statistics and Data Center, Durham, NC; Ying Zhang, Pennsylvania State University College of Medicine, Hershey, PA; Everett E. Vokes, University of Chicago Medical Center, Chicago, IL; Joan H. Schiller, Inova Dwight and Martha Schar Cancer Institute, Falls Church, VA; Jeffrey D. Bradley and Ramaswamy Govindan, Washington University School of Medicine, St Louis, MO; Karen Kelly, University of California Davis, Sacramento, CA; Walter J. Curran Jr, Winship Cancer Institute of Emory University, Atlanta, GA; Steven E. Schild, Mayo Clinic Arizona, Scottsdale, AZ; Benjamin Movsas, Henry Ford Health System, Detroit, MI; Gerald Clamon, University of Iowa Hospital and Clinics, Iowa City, IA; George R. Blumenschein, University of Texas MD Anderson Cancer Center, Houston, TX; Mark A. Socinski, Florida Hospital Cancer Institute, Orlando, FL; Wallace L. Akerley, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; and Herbert H. Pang, University of Hong Kong, Hong Kong Special Administrative Region, People's Republic of China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.71.4758DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5578390PMC
September 2017

First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.

N Engl J Med 2017 06;376(25):2415-2426

From the Ohio State University Comprehensive Cancer Center, Columbus (D.P.C.); LungenClinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf (M.R.), and Thoraxklinik, Heidelberg University Hospital, Heidelberg (M.S.) - both in Germany; Hospital Universitario Doce de Octubre, Centro Nacional de Investigaciones Oncológicas and Universidad Complutense, Madrid (L.P.-A., J.C.J.), Vall d'Hebron University Hospital, Barcelona (E.F.), and Hospital Universitario Insular de Gran Canaria, Las Palmas (D.R.-A.) - all in Spain; H. Lee Moffitt Cancer Center, Tampa, FL (B.C.); Vanderbilt University Medical Center, Nashville (L. Horn); Antoni van Leeuwenhoek Ziekenhuis, Amsterdam (M.M.H.), and University of Groningen, Universitair Medisch Centrum Groningen, Groningen (T.J.N.H.) - both in the Netherlands; Prof. Dr. Ion Chiricuta Institute of Oncology and University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania (T.-E.C.); Baptist Health Lexington, Lexington, KY (F.B.); Duke University, Durham, NC (N.R.); Lehigh Valley Health Network, Allentown (S.N.), Fox Chase Cancer Center, Philadelphia (H.B.), and University of Pittsburgh Medical Center Cancer Center, Pittsburgh (L.C.V., M.A.S.) - all in Pennsylvania; Juravinski Cancer Centre, Hamilton, ON, Canada (R.J.); Oncology Department, Lausanne University Hospital, Lausanne, Switzerland (S.P.); Santa Maria Hospital, Terni, Italy (E.M.); Hollings Cancer Center, Charleston, SC (J.M.W.); Department of Thoracic-Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston (G.R.B.); Klinika Pneumologie a Hrudní Chirurgie, Nemocnice Na Bulovce, Prague, Czech Republic (L. Havel, J.K.); and Bristol-Myers Squibb, Princeton, NJ (H.C., W.J.G., P.B., A.C.C.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1613493DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6487310PMC
June 2017

Cardiac Toxicity After Radiotherapy for Stage III Non-Small-Cell Lung Cancer: Pooled Analysis of Dose-Escalation Trials Delivering 70 to 90 Gy.

J Clin Oncol 2017 May 23;35(13):1387-1394. Epub 2017 Jan 23.

Kyle Wang, Michael J. Eblan, Matthew Lipner, Timothy M. Zagar, Panayiotis Mavroidis, Carrie B. Lee, Brian C. Jensen, Julian G. Rosenman, and Lawrence B. Marks, University of North Carolina Hospitals; Allison M. Deal and Yue Wang, Lineberger Comprehensive Cancer Center Biostatistics Core, University of North Carolina Hospitals, Chapel Hill; Thomas E. Stinchcombe, Duke University Hospitals, Durham, NC; and Mark A. Socinski, Florida Hospital Cancer Institute, Orlando, FL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.0229DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455462PMC
May 2017

Necitumumab plus Gemcitabine and Cisplatin as First-Line Therapy in Patients with Stage IV EGFR- Expressing Squamous Non-Small-Cell Lung Cancer: German Subgroup Data from an Open-Label, Randomized Controlled Phase 3 Study (SQUIRE).

Oncol Res Treat 2016 2;39(9):539-47. Epub 2016 Aug 2.

Department of Thoracic Oncology, Airway Research Center North (ARCN), German Center for Lung Research (DZL), German Center for Lung Research (DZL), LungenClinic Grosshansdorf, Grosshansdorf, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000448085DOI Listing
April 2017

Understanding Mechanisms of Resistance in the Epithelial Growth Factor Receptor in Non-Small Cell Lung Cancer and the Role of Biopsy at Progression.

Oncologist 2017 01 7;22(1):3-11. Epub 2016 Nov 7.

Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2016-0285DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5313265PMC
January 2017

Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer.

J Clin Oncol 2016 12 31;34(34):4079-4085. Epub 2016 Oct 31.

Shirish M. Gadgeel, Karmanos Cancer Institute, Wayne State University, Detroit, MI; Alice T. Shaw, Massachusetts General Hospital; Leena Gandhi, Dana-Farber Cancer Institute, Boston, MA; Ramaswamy Govindan, Washington University School of Medicine, St Louis, MO; Mark A. Socinski, University of Pittsburgh, Pittsburgh, PA; D. Ross Camidge, University of Colorado Cancer Center, Denver, CO; Alberto Chiappori, Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Sai-Hong Ignatius Ou, University of California at Irvine, Orange, CA; Luigi De Petris, Karolinska Institutet, Stockholm, Sweden; Dong-Wan Kim, Seoul National University Hospital, Seoul; Ji-Youn Han, Lung Cancer Centre, National Cancer Centre, Goyang, South Korea; Denis L. Moro-Sibilot, Service de Pneumologie; Michael Duruisseaux, Centre Hospitalier Universitaire de Grenoble, Grenoble; Eric Dansin, Centre Oscar Lambret, Lille, France; Lucio Crino, Santa Maria della Misericordia Hospital, Perugia; Tommaso De Pas, European Institute of Oncology, Milan, Italy; Antje Tessmer, Evangelische Lungenklinik Berlin, Berlin, Germany; James Chih-Hsin Yang, Graduate Institute of Oncology and Cancer Research Centre, National Taiwan University, Taipei, Taiwan; and Walter Bordogna, Sophie Golding, and Ali Zeaiter, F. Hoffmann-La Roche, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.68.4639DOI Listing
December 2016

Paradoxical functions of ZEB1 in -mutant lung cancer: tumor suppressor and driver of therapeutic resistance.

J Thorac Dis 2016 Nov;8(11):E1528-E1531

Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA, USA;; Department of Medicine, Division of Hematology-Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2016.11.59DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5179406PMC
November 2016

Isolating the Role of Bevacizumab in Elderly Patients With Previously Untreated Nonsquamous Non-Small Cell Lung Cancer: Secondary Analyses of the ECOG 4599 and PointBreak Trials.

Am J Clin Oncol 2016 10;39(5):441-7

*Abramson Cancer Center, University of Pennsylvania, Philadelphia †University of Pittsburgh Medical Center, UPMC Cancer Pavilion, Pittsburgh, PA ‡Feinberg School of Medicine, Northwestern University, Chicago, IL §Genentech Inc., South San Francisco, CA ∥Harold C. Simmons Cancer Center, University of Texas Southwestern, Dallas, TX ¶Winship Cancer Institute of Emory University, Atlanta, GA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000163DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5016219PMC
October 2016

Best Practices in Treatment Selection for Patients With Advanced NSCLC.

Cancer Control 2016 Oct;23(4 Suppl):2-14

Florida Hospital Cancer Institute, Orlando, FL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1073274816023004S01DOI Listing
October 2016

Immune checkpoint blockade in lung cancer.

Discov Med 2016 08;22(119):55-65

Division of Hematology/Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15232, USA.

View Article

Download full-text PDF

Source
August 2016

HSP90 inhibitors in lung cancer: promise still unfulfilled.

Clin Adv Hematol Oncol 2016 May;14(5):346-56

University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania.

View Article

Download full-text PDF

Source
May 2016

Is there a role of nab-paclitaxel in the treatment of advanced non-small cell lung cancer? The data suggest yes.

Eur J Cancer 2016 Mar 12;56:162-171. Epub 2016 Feb 12.

University of Pittsburgh Cancer Institute, Lung Cancer Program, 5150 Center Avenue, Pittsburgh, PA 15232, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2015.12.022DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4844000PMC
March 2016

KRAS mutant lung cancer: progress thus far on an elusive therapeutic target.

Clin Transl Med 2015 Dec 14;4(1):35. Epub 2015 Dec 14.

University of Pittsburgh Cancer Institute, 5117 Centre Avenue, Office: Suite 2.18e, Pittsburgh, PA, 15232, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40169-015-0075-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4678136PMC
December 2015

Near complete response after single dose of nivolumab in patient with advanced heavily pre-treated KRAS mutant pulmonary adenocarcinoma.

Exp Hematol Oncol 2015 14;4:34. Epub 2015 Dec 14.

Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA USA ; Division of Hematology-Oncology, University of Pittsburgh Cancer Institute, 5117 Centre Avenue, Office: Suite 2.18e, Pittsburgh, PA 15232 USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40164-015-0029-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4678465PMC
December 2015

Advances in Immuno-Oncology: Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer-Introduction.

Authors:
Mark A Socinski

Semin Oncol 2015 Oct 11;42 Suppl 2:S1-2. Epub 2015 Sep 11.

Co-Leader, UPCI Lung Cancer Program University of Pittsburgh Medical Center Pittsburgh, PA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2015.09.018DOI Listing
October 2015

Incorporating Immunotherapy Into the Treatment of Non-Small Cell Lung Cancer: Practical Guidance for the Clinic.

Authors:
Mark A Socinski

Semin Oncol 2015 Oct 11;42 Suppl 2:S19-28. Epub 2015 Sep 11.

Co-Leader, UPCI Lung Cancer Program, University of Pittsburgh Medical Center, Pittsburgh, PA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2015.09.017DOI Listing
October 2015

The role of anti-angiogenesis in non-small-cell lung cancer: an update.

Curr Oncol Rep 2015 Jun;17(6):26

Lung Cancer Program, University of Pittsburgh Cancer Institute, 5150 Centre Avenue, 5th Floor Cancer Pavilion, Room 567, Pittsburgh, PA, 15232, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-015-0448-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4836185PMC
June 2015

Metastasis of breast carcinoma to the maxillary sinus.

Breast J 2014 May-Jun;20(3):318-9. Epub 2014 Apr 2.

Division of Hematology and Oncology, University of Pittsburgh, Pittsburgh, Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/tbj.12265DOI Listing
May 2015

Alternative strategy to achieve increased overall survival and better quality of life in patients with second-line advanced non-small-cell lung cancer.

J Clin Oncol 2015 Feb 12;33(5):522-3. Epub 2015 Jan 12.

University of Pittsburgh Schools of the Health Sciences, Pittsburgh, PA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.58.1603DOI Listing
February 2015

Quality of life analyses from the randomized, open-label, phase III PointBreak study of pemetrexed-carboplatin-bevacizumab followed by maintenance pemetrexed-bevacizumab versus paclitaxel-carboplatin-bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.

J Thorac Oncol 2015 Feb;10(2):353-9

*Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN; †Feinberg School of Medicine, Northwestern University, Chicago, IL; ‡Ocala Oncology, Ocala, FL and US Oncology Research, Inc., Houston, TX; §David Geffen School of Medicine at UCLA/Translational Research in Oncology-US, Los Angeles, CA; ║Northwest Georgia Oncology Centers, Marietta, GA; ¶Washington University School of Medicine, St. Louis, MO; #Tulsa Cancer Institute, Tulsa, OK; **Eli Lilly and Company, Indianapolis, IN; ††University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA; and ‡‡Rush University Medical Center, Chicago, IL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000277DOI Listing
February 2015

Personalized treatment of EGFR mutant and ALK-positive patients in NSCLC.

Expert Opin Pharmacother 2014 Dec 10;15(18):2693-708. Epub 2014 Nov 10.

Lung Cancer Program, University of Pittsburgh Cancer Institute , Pittsburgh, PA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14656566.2014.971013DOI Listing
December 2014

Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer.

J Clin Oncol 2014 Dec 10;32(35):4012-9. Epub 2014 Nov 10.

Joachim von Pawel, Asklepios Fachkliniken München-Gauting, Gauting; Jörg Mezger, St Vincentius-Kliniken Karlsruhe, Karlsruhe; Martin Steins, Thoraxklinik am Universitätsklinikum, Heidelberg; Wolfgang Schütte, Krankenhaus Martha-Maria Halle-Dölau, Halle; Martin Reck, Krankenhaus Großhansdorf, Großhansdorf, Germany; Robert Jotte, Rocky Mountain Cancer Center, Denver, CO, and US Oncology, Houston, TX; David R. Spigel, Sarah Cannon Research Institute, Nashville, TN; Mary E.R. O'Brien, Royal Marsden National Health Service (NHS) Foundation Trust, Surrey; Paul Lorigan, Christie NHS Foundation Trust, Manchester, United Kingdom; Mark A. Socinski, University of Pittsburgh Medical Center, Pittsburgh, PA; Léon Bosquée, Centre Hospitalier Universitaire Sart-Tilman, Liège; Kristiaan Nackaerts, Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium; Jeffrey Bubis, Cancer Specialists of North Florida, Jacksonville, FL; José M. Trigo, Hospital Universitario Virgen de la Victoria, Malaga; Manuel Domine, Fundación Jiménez Diaz, Universidad Autónoma de Madrid, Madrid, Spain; Philip Clingan, Southern Medical Day Care Centre, Wollongong, New South Wales, Australia; Frances A. Shepherd, University Health Network, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Shaoyi Li and Markus F. Renschler, Celgene, Summit, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.54.5392DOI Listing
December 2014

A single-arm phase II trial of pazopanib in patients with advanced non-small cell lung cancer with non-squamous histology with disease progression on bevacizumab containing therapy.

Lung Cancer 2014 Nov 26;86(2):288-90. Epub 2014 Aug 26.

University of North Carolina at Chapel Hill, 170 Manning Drive, Physician's Office Building 3rd Floor, Chapel Hill, NC 27599-7305, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2014.08.011DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4836183PMC
November 2014

Targeted therapy vs chemotherapy: which has had more impact on survival in lung cancer? The significant impact of chemotherapy in lung cancer.

Authors:
Mark A Socinski

Clin Adv Hematol Oncol 2014 Nov;12(11):763, 767-8

University of Pittsburgh Medical Center, Pittsburgh, PA.

View Article

Download full-text PDF

Source
November 2014

Consensus report of a joint NCI thoracic malignancies steering committee: FDA workshop on strategies for integrating biomarkers into clinical development of new therapies for lung cancer leading to the inception of "master protocols" in lung cancer.

J Thorac Oncol 2014 Oct;9(10):1443-8

*Clinical Investigations Branch, Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, Bethesda, MD; †Offices of Hematology and Oncology Products, Center for Drug Evaluation and Research U.S. Food and Drug Administration, Silver Spring, MD; ‡University of Pittsburgh Medical Center, Pittsburgh, PA; §University of Utah, Salt Lake City, UT; ‖Duke University Medical Center, Durham, NC; ¶Biometric Research Branch, Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, Bethesda, MD; and #University of Colorado, School of Medicine, Denver, CO.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000314DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4165474PMC
October 2014

Highlights in NSCLC from the 2014 ASCO meeting.

Authors:
Mark A Socinski

Clin Adv Hematol Oncol 2014 Oct;12(10 Suppl 18):16-9

University of Pittsburgh, Pittsburgh, Pennsylvani.

View Article

Download full-text PDF

Source
October 2014

Inherited variation in the ATP-binding cassette transporter ABCB1 and survival after chemotherapy for stage III-IV lung cancer.

J Thorac Oncol 2014 Sep;9(9):1264-71

*University of Pittsburgh Cancer Institute and †Department of Epidemiology, University of Pittsburgh Graduate School of Public Health; ‡Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh School of Medicine; §Department of Medicine, University of Pittsburgh School of Medicine; ‖Department of Cardiothoracic Surgery, University of Pittsburgh School of Medicine; ¶Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15560864153067
Publisher Site
http://dx.doi.org/10.1097/JTO.0000000000000262DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4134100PMC
September 2014

Assessing response to treatment in non--small-cell lung cancer: role of tumor volume evaluated by computed tomography.

Clin Lung Cancer 2014 Mar 13;15(2):103-9. Epub 2013 Nov 13.

University of Pittsburgh, Hillman Cancer Center, Pittsburgh, PA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2013.11.001DOI Listing
March 2014

Temsirolimus therapy in a patient with lung adenocarcinoma harboring an FBXW7 mutation.

Lung Cancer 2014 Feb 1;83(2):300-1. Epub 2013 Dec 1.

University of Pittsburgh Cancer Institute, University of Pittsburgh, School of Medicine/Hematology-Oncology, Lung and Thoracic Malignancies Program, Pittsburgh, PA 15232, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2013.11.018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4836187PMC
February 2014

CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer.

J Thorac Oncol 2014 Feb;9(2):214-21

*Department of Thoracic Oncology, Massachusetts General Hospital, Boston, Massachusetts; †Department of Oncology, Alliance Statistics and Data Center, Duke University Medical Center, Durham, North Carolina; ‡Department of Oncology, Ohio State University Medical Center, Columbus, Ohio; §Department of Oncology, University of North Carolina, Chapel Hill, North Carolina; ‖Department of Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; ¶Department of Oncology, Kinston Medical Specialists, P.A., Kinston, North Carolina; #Department of Oncology, University of Chicago, Chicago, Illinois; and **Department of Oncology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000071DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4284815PMC
February 2014

Immunotherapy in lung cancer.

Transl Lung Cancer Res 2014 Feb;3(1):2-14

University of Pittsburgh Cancer Institute, University of Pittsburgh, School of Medicine/Hematology-Oncology, Lung and Thoracic Malignancies Program, Pittsburgh, PA 15232, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2218-6751.2013.10.13DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4367610PMC
February 2014

Patient-reported neuropathy and taxane-associated symptoms in a phase 3 trial of nab-paclitaxel plus carboplatin versus solvent-based paclitaxel plus carboplatin for advanced non-small-cell lung cancer.

J Thorac Oncol 2014 Jan;9(1):83-90

*McGill University, Montreal, Quebec, Canada; †Kinki University Faculty of Medicine, Osaka-Sayama, Japan; ‡Clearview Cancer Institute, Huntsville, Alabama; §The Center for Cancer and Blood Disorders, Fort Worth, Texas; ‖Essex Oncology of New Jersey, Belleville, New Jersey; ¶Saitama Cancer Center, Saitama, Japan; #Celgene Corporation, Summit, New Jersey; and **University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000011DOI Listing
January 2014

RET rearrangements in lung adenocarcinoma and radiation.

J Thorac Oncol 2014 Jan;9(1):118-20

Departments of *Pathology, †Pharmacology, University of Pittsburgh; and 3University of Pittsburgh Cancer Institute, University of Pittsburgh, School of Medicine/Hematology-Oncology, Pittsburgh, Pennsylvania.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15560864153017
Publisher Site
http://dx.doi.org/10.1097/JTO.0000000000000015DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4836180PMC
January 2014

Management of normal tissue toxicity associated with chemoradiation (primary skin, esophagus, and lung).

Cancer J 2013 May-Jun;19(3):231-7

Division of Hematology/Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0b013e31829453fbDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4836174PMC
December 2013

PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.

J Clin Oncol 2013 Dec 21;31(34):4349-57. Epub 2013 Oct 21.

Jyoti D. Patel, Northwestern University; Philip Bonomi, Rush University Medical Center, Chicago, IL; Mark A. Socinski, University of Pittsburgh, Pittsburgh, PA; Edward B. Garon, University of California at Los Angeles, Los Angeles, CA; Craig H. Reynolds, US Oncology Research, Ocala, FL; David R. Spigel, Sarah Cannon Research Institute-Tennessee Oncology, Nashville, TN; Mark R. Olsen, Tulsa Cancer Institute, Tulsa, OK; Robert C. Hermann, Northwest Georgia Oncology Centers, Marietta, GA; Robert M. Jotte, Rocky Mountain Cancer Centers, Denver, CO; Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Donald A. Richards, US Oncology Research, Tyler, TX; Susan C. Guba, Jingyi Liu, Bente Frimodt-Moller, and William J. John, Eli Lilly, Indianapolis, IN; Coleman K. Obasaju and Eduardo J. Pennella, Lilly USA, Indianapolis, IN; and Ramaswamy Govindan, Washington University School of Medicine, St. Louis, MO.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.47.9626DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881367PMC
December 2013

Personalizing therapy in advanced non-small cell lung cancer.

Semin Respir Crit Care Med 2013 Dec 20;34(6):822-36. Epub 2013 Nov 20.

Lung and Thoracic Malignancies Program, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania.

View Article

Download full-text PDF

Source
https://www.thieme-connect.com/products/ejournals/pdf/10.105
Web Search
http://www.thieme-connect.de/DOI/DOI?10.1055/s-0033-1358552
Publisher Site
http://dx.doi.org/10.1055/s-0033-1358552DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4836173PMC
December 2013

Phase I trial of carboplatin and etoposide in combination with panobinostat in patients with lung cancer.

Anticancer Res 2013 Oct;33(10):4475-81

University of Pittsburgh Cancer Institute, UPMC Cancer Pavilion, 5150 Centre Avenue (555), Pittsburgh, PA 15232, U.S.A.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4157617PMC
October 2013

Do oncogenic drivers exist in squamous cell carcinoma of the lung?

Oncology (Williston Park) 2013 Sep;27(9):906, 913-4

University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467095PMC
September 2013

The prognostic and predictive value of KRAS oncogene substitutions in lung adenocarcinoma.

Cancer 2013 Jun 22;119(12):2268-74. Epub 2013 Mar 22.

University of Pittsburgh Cancer Institute, School of Medicine/Hematology-Oncology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.28039
Publisher Site
http://dx.doi.org/10.1002/cncr.28039DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3674175PMC
June 2013

Rationale for chemotherapy, immunotherapy, and checkpoint blockade in SCLC: beyond traditional treatment approaches.

J Thorac Oncol 2013 May;8(5):587-98

Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, Tennessee 37203, USA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15560864153281
Publisher Site
http://dx.doi.org/10.1097/JTO.0b013e318286cf88DOI Listing
May 2013

The clinical viewpoint: definitions, limitations of RECIST, practical considerations of measurement.

Clin Cancer Res 2013 May;19(10):2629-36

University of Pittsburgh Cancer Institute, Division of Hematology/Oncology, Pittsburgh, Pennsylvania 15232, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-12-2935DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4844002PMC
May 2013

A retrospective analysis of VeriStrat status on outcome of a randomized phase II trial of first-line therapy with gemcitabine, erlotinib, or the combination in elderly patients (age 70 years or older) with stage IIIB/IV non-small-cell lung cancer.

J Thorac Oncol 2013 Apr;8(4):443-51

Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 170 Manning Drive, Physician’s Office Building, 3rd Floor, Chapel Hill, NC 27599-7305, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0b013e3182835577DOI Listing
April 2013

The impact of local and regional disease extent on overall survival in patients with advanced stage IIIB/IV non-small cell lung carcinoma.

Int J Radiat Oncol Biol Phys 2012 Nov 1;84(3):e385-92. Epub 2012 Aug 1.

Department of Radiation Oncology, University of North Carolina, Chapel Hill, North Carolina 27599-7512, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2012.04.045DOI Listing
November 2012

Clinical roundtable monograph: Recent advances in taxanes for the first-line treatment of advanced non-small cell lung cancer.

Clin Adv Hematol Oncol 2012 Oct;10(10 Suppl 18):1-16

University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

View Article

Download full-text PDF

Source
October 2012

Highlights in NSCLC From the 2012 American Society of Clinical Oncology Annual Meeting.

Authors:
Mark A Socinski

Clin Adv Hematol Oncol 2012 Aug;10(8 Suppl 11):1-24

University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.

View Article

Download full-text PDF

Source
August 2012